GH Research $117.5 million follow-on offering
We advised GH Research on the offering
Experience
To find Davis Polk deals and cases of particular interest, select filters based on practice, industry, region, lawyer and keyword.
Filters
Avalyn Pharma $300 million IPO
We advised the underwriters on the IPO
Mabwell Bioscience HK$1.2 billion IPO
We advised Mabwell on its IPO and HKEX listing
Maze Therapeutics $150 million offering
We advised the sole underwriter on the offering
JATT II Acquisition $60 million SPAC IPO
We advised the sole bookrunning manager in connection with the IPO
Revolution Medicines $2.2 billion common stock and convertible notes offerings
We advised the underwriters on the concurrent offerings
Adagene $70 million registered direct offering
We advised Adagene on the offering
AN2 Therapeutics $80 million at-the-market offering
We advised the sales agent on the offering
CytomX Therapeutics $250 million follow-on offering
We advised the representatives of the underwriters on the offering
Novartis $11 billion notes offering
We advised Novartis on the investment-grade debt offering